Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether À Go-Go K+ Channel

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Lin, Huixian ^a   Li, Zhe ^c   Chen, Chang ^c   Luo, Xiaobin ^a,b,c   Xiao, Jiening ^a   Dong, Deli ^c   Lu, Yanjie ^c   Yang, Baofeng ^c   Wang, Zhiguo ^a,b,c  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ETHER A GO GO 1 POTASSIUM CHANNEL; MICRORNA; MICRORNA 34; POTASSIUM CHANNEL; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE; DRUG DERIVATIVE; E2F1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; KCNH1 PROTEIN, HUMAN; MIRN34 MICRORNA, HUMAN; NUTLIN 3; PIFITHRIN; PIPERAZINE DERIVATIVE; POTASSIUM CHANNEL HERG; TOLUENE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; TRANSACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BENZOTHIAZOLES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; E2F1 TRANSCRIPTION FACTOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; IMIDAZOLES; MICRORNAS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PIPERAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957914650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020362     Document Type: Article

References (48)

1. Pardo LA, Stühmer W, (2008) Eag1: an emerging oncological target. Cancer Res 68: 1611-1613.
2. Wang Z, (2004) Roles of K+ channels in regulating tumor cell proliferation and apoptosis. Pflugers Arch 448: 274-286.
3. Stühmer W, Alves F, Hartung F, Zientkowska M, Pardo LA, (2006) Potassium channels as tumour markers. FEBS Lett 580: 2850-2852.
4. Bauer CK, Schwarz JR, (2001) Physiology of EAG K+ channels. J Membr Biol 182: 1-15.
5. Ding XW, Luo HS, Jin X, Yan JJ, Ai YW, (2007) Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med Oncol 24: 345-350.
6. Ding XW, Wang XG, Luo HS, Tan SY, Gao S, et al. (2008) Expression and prognostic roles of Eag1 in resected esophageal squamous cell carcinomas. Dig Dis Sci 53: 2039-2044.
7. Ding XW, Yan JJ, An P, Lu P, Luo HS, (2007) Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines. World J Gastroenterol 13: 1257-1261.
8. Farias LM, Ocaña DB, Díaz L, Larrea F, Avila-Chávez E, et al. (2004) Ether á go-go potassium channels as human cervical cancer markers. Cancer Res 64: 6996-7001.
9. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, et al. (2006) Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 5: 41-53.
10. Mello de Queiroz F, Suarez-Kurtz G, Stuhmer W, Pardo Lam, (2006) Ether a go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 5: 42.
11. Meyer R, Heinemann SH, (1998) Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 508: 49-56.
12. Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, et al. (2001) Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether á-gogo K+ channel. Receptors Channels 7: 345-356.
13. Pardo LA, Brüggemann A, Camacho J, Stühmer W, (1998) Cell cycle-related changes in the conducting properties of r-eag K+ channels. J Cell Biol 143: 767-775.
14. Pardo LA, del Camino D, Sánchez A, Alves F, Brüggemann A, et al. (1999) Oncogenic potential of EAG K+ channels. EMBO J 18: 5540-5547.
15. Patt S, Preussat K, Beetz C, Kraft R, Schrey M, et al. (2004) Expression of ether à go-go potassium channels in human gliomas. Neurosci Lett 368: 249-253.
16. Spitzner M, Martins JR, Soria RB, Ousingsawat J, Scheidt K, et al. (2008) Eag1 and Bestrophin 1 are up-regulated in fast-growing colonic cancer cells. J Biol Chem 283: 7421-7428.
17. Wadhwa S, Wadhwa P, Dinda AK, Gupta NP, (2009) Differential expression of potassium ion channels in human renal cell carcinoma. Int Urol Nephrol 41: 251-257.
18. Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stuhmer W, et al. (2006) Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference. J Biol Chem 281: 13030-13037.
19. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, et al. (2007) Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 67: 7343-7349.
20. Gao H, Xiao J, Yang B, Sun Q, Lin H, et al. (2006) A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anti-cancer effects. Mol Pharmacol 70: 1621-1629.
21. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355.
22. Morishita R, Aoki M, Kaneda Y, (2001) Decoy oligodeoxynucleotides as novel cardiovascular drugs for cardiovascular disease. Ann NY Acad Sci 947: 294-301.
23. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, et al. (1997) In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 13: 894-899.
24. Lin H, Xiao J, Luo X, Xu C, Gao H, et al. (2007) Overexpression HERG K+ channel gene mediates cell-growth signals on activation of oncoproteins Sp1 and NF-κB and inactivation of tumor suppressor Nkx3.1. J Cell Physiol 212: 137-147.
25. Crosby ME, Almasan A, (2004) Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther 3: 1208-1211.
26. DeGregori J, Johnson DG, (2006) Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6: 739-748.
27. Rogoff HA, Kowalik TF, (2004) Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell Cycle 3: 845-846.
28. Lu Y, Xiao J, Lin H, Bai Y, Luo X, et al. (2009) Complex antisense inhibitors offer a superior approach for microRNA research and therapy. Nucleic Acids Res 37: e24-e33.
29. Napp J, Monje F, Stühmer W, Pardo LA, (2005) Glycosylation of Eag1 (Kv10.1) potassium channels. Intracellular trafficking and functional consequences. J Biol Chem 280: 29506-29512.
30. Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, et al. (2010) miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127: 2768-2776.
31. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H, (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 104: 15472-15477.
32. Welch C, Chen Y, Stallings RL, (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017-5022.
33. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1135.
34. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
35. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, et al. (2008) Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.Cancer Res 68: 3193-3203.
36. Hermeking H, (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
37. Ason B, Darnell DK, Wittbrodt B, Berezikov E, Kloosterman WP, et al. (2006) Differences in vertebrate microRNA expression. Proc Natl Acad Sci USA103: 14385-14389.
38. Kapsimali M, (2010) The wide variety of miRNA expression profiles in the developing and mature CNS. Macro roles for microRNAs in the life and death of neurons, by de Strooper B & Christen Y (eds) pp11, Springer-Verlag Berlin Heidelberg.
39. Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gymnopoulos M, et al. (2008) Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem 283: 36234-36240.
40. Wang L, Wang R, Herrup K, (2007) E2F1 works as a cell cycle suppressor in mature neurons. J Neurosci 27: 12555-12564.
41. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569-7576.
42. Lin H, Xiao J, Luo X, Chen G, Wang Z, (2009) Transcriptional control of pacemaker channel genes HCN2 and HCN4 by Sp1 and implications in re-expression of these genes in hypertrophic heart. Cell Physiol Biochem 23: 317-326.
43. Luo X, Lin H, Lu Y, Li B, Xiao J, et al. (2007) Transcriptional activation by stimulating protein 1 and post-transcriptional repression by muscle-specific microRNAs of IKs-encoding genes and potential implications in regional heterogeneity of their expressions. J Cell Physiol 212: 358-367.
44. Luo X, Xiao J, Lin H, Lu Y, Yang B, et al. (2007) Genomic structure, transcriptional control and tissue distribution of human ERG1 and KCNQ1 genes. Am J Physiol 294: H1371-H1380.
45. Yang B, Lin H, Xiao J, Lu Y, Luo X, et al. (2007) The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491.
46. Luo X, Lin H, Xiao J, Zhang Y, Lu Y, et al. (2008) Downregulation of miRNA-1/miRNA-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 2008; 283: 20045-52.
47. Xu C, Lu Y, Lin H, Xiao J, Wang H, et al. (2007) The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis via targeting HSP60/HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120: 3045-3052.
48. Wang H, Zhang Y, Cao L, Han H, Wang J, et al. (2002) HERG K+ channel: A regulator of tumor cell apoptosis and proliferation. Cancer Res 62: 4843-4848.